Karin Eastham - Net Worth and Insider Trading
Karin Eastham Net Worth
The estimated net worth of Karin Eastham is at least $3 Million dollars as of 2024-08-26. Karin Eastham is the Director of Illumina Inc and owns about 10,838 shares of Illumina Inc (ILMN) stock worth over $1 Million. Karin Eastham is the Director of Veracyte Inc and owns about 33,228 shares of Veracyte Inc (VCYT) stock worth over $1 Million. Karin Eastham is also the Director of Nektar Therapeutics and owns about 13,033 shares of Nektar Therapeutics (NKTR) stock worth over $17,725. Details can be seen in Karin Eastham's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Karin Eastham has not made any transactions after 2024-07-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Karin Eastham
Karin Eastham Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Karin Eastham owns 5 companies in total, including Nektar Therapeutics (NKTR) , Veracyte Inc (VCYT) , and Geron Corp (GERN) among others .
Click here to see the complete history of Karin Eastham’s form 4 insider trades.
Insider Ownership Summary of Karin Eastham
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
NKTR | Nektar Therapeutics | 2022-09-13 | director |
VCYT | Veracyte Inc | 2024-07-16 | director |
GERN | Geron Corp | 2009-03-30 | director |
![]() | ![]() | 2019-09-09 | director |
![]() | ![]() | 2019-01-02 | director |
Karin Eastham Latest Holdings Summary
Karin Eastham currently owns a total of 3 stocks. Among these stocks, Karin Eastham owns 10,838 shares of Illumina Inc (ILMN) as of January 2, 2019, with a value of $1 Million and a weighting of 56.42%. Karin Eastham owns 33,228 shares of Veracyte Inc (VCYT) as of July 16, 2024, with a value of $1 Million and a weighting of 42.88%. Karin Eastham also owns 13,033 shares of Nektar Therapeutics (NKTR) as of September 13, 2022, with a value of $17,725 and a weighting of 0.71%.
Latest Holdings of Karin Eastham
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
ILMN | Illumina Inc | 2019-01-02 | 10,838 | 130.42 | 1,413,492 |
VCYT | Veracyte Inc | 2024-07-16 | 33,228 | 32.33 | 1,074,261 |
NKTR | Nektar Therapeutics | 2022-09-13 | 13,033 | 1.36 | 17,725 |
Holding Weightings of Karin Eastham
Karin Eastham Form 4 Trading Tracker
According to the SEC Form 4 filings, Karin Eastham has made a total of 0 transactions in Illumina Inc (ILMN) over the past 5 years. The most-recent trade in Illumina Inc is the sale of 5,000 shares on January 2, 2019, which brought Karin Eastham around $1 Million.
According to the SEC Form 4 filings, Karin Eastham has made a total of 9 transactions in Veracyte Inc (VCYT) over the past 5 years, including 0 buys and 9 sells. The most-recent trade in Veracyte Inc is the sale of 7,500 shares on July 16, 2024, which brought Karin Eastham around $187,500.
According to the SEC Form 4 filings, Karin Eastham has made a total of 1 transactions in Nektar Therapeutics (NKTR) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Nektar Therapeutics is the sale of 21,267 shares on September 13, 2022, which brought Karin Eastham around $76,774.
Insider Trading History of Karin Eastham
- 1
Karin Eastham Trading Performance
Karin Eastham Ownership Network
Ownership Network List of Karin Eastham
Ownership Network Relation of Karin Eastham
![Insider Network Chart](https://static.gurufocus.com/insider-network.png)
Karin Eastham Owned Company Details
What does Nektar Therapeutics do?
Who are the key executives at Nektar Therapeutics?
Karin Eastham is the director of Nektar Therapeutics. Other key executives at Nektar Therapeutics include SVP & General Counsel Mark Andrew Wilson , Chief R&D Officer Jonathan Zalevsky , and director & President & CEO Howard W Robin .
Nektar Therapeutics (NKTR) Insider Trades Summary
Over the past 18 months, Karin Eastham made no insider transaction in Nektar Therapeutics (NKTR). Other recent insider transactions involving Nektar Therapeutics (NKTR) include a net sale of 111,800 shares made by Howard W Robin , a net sale of 52,375 shares made by Jonathan Zalevsky , and a net sale of 41,460 shares made by Mark Andrew Wilson .
In summary, during the past 3 months, insiders sold 46,898 shares of Nektar Therapeutics (NKTR) in total and bought 0 shares, with a net sale of 46,898 shares. During the past 18 months, 289,853 shares of Nektar Therapeutics (NKTR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 289,853 shares.
Nektar Therapeutics (NKTR)'s detailed insider trading history can be found in Insider Trading Tracker table.
Nektar Therapeutics Insider Transactions
Karin Eastham Mailing Address
Above is the net worth, insider trading, and ownership report for Karin Eastham. You might contact Karin Eastham via mailing address: C/o Burnham Institute For Medical Resear, 10901 N. Torrey Pines Road, La Jolla Ca 92037.